Twist Bioscience Corporation (NASDAQ:TWST) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Twist Bioscience Corporation (NASDAQ:TWST) has been assigned an average rating of “Moderate Buy” from the ten research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $98.30.

TWST has been the topic of several research analyst reports. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a report on Monday, August 3rd. Robert W. Baird upped their target price on Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. UBS Group set a $89.00 target price on Twist Bioscience in a research report on Monday, June 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, June 24th. Finally, Leerink Partners set a $110.00 price objective on shares of Twist Bioscience in a report on Thursday, July 16th.

Insider Activity at Twist Bioscience

In related news, CFO Adam Laponis sold 2,399 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $94.33, for a total value of $226,297.67. Following the transaction, the chief financial officer directly owned 110,276 shares of the company’s stock, valued at approximately $10,402,335.08. This trade represents a 2.13% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Dennis Cho sold 14,205 shares of Twist Bioscience stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $89.75, for a total value of $1,274,898.75. Following the completion of the sale, the insider owned 105,141 shares in the company, valued at approximately $9,436,404.75. The trade was a 11.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 193,099 shares of company stock worth $24,026,581 over the last three months. Company insiders own 3.08% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quarry LP acquired a new stake in shares of Twist Bioscience in the third quarter worth approximately $28,000. Western Wealth Management LLC acquired a new position in Twist Bioscience in the 1st quarter valued at $31,000. Strs Ohio acquired a new position in Twist Bioscience in the 1st quarter valued at $33,000. Strategic Advocates LLC lifted its holdings in Twist Bioscience by 562.7% in the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after purchasing an additional 906 shares in the last quarter. Finally, SBI Securities Co. Ltd. lifted its holdings in Twist Bioscience by 68.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after purchasing an additional 571 shares in the last quarter.

Twist Bioscience Stock Performance

TWST stock opened at $141.38 on Monday. Twist Bioscience has a 52-week low of $23.30 and a 52-week high of $155.44. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The firm has a market cap of $8.87 billion, a P/E ratio of -63.68 and a beta of 2.14. The company’s 50-day simple moving average is $106.95 and its 200-day simple moving average is $74.01.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The business had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. Twist Bioscience’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.33 EPS. As a group, equities analysts forecast that Twist Bioscience will post -2.12 EPS for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.